Home » Stocks » FSTX

F-star Therapeutics, Inc. (FSTX)

Stock Price: $9.07 USD 0.02 (0.22%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $9.00 -0.07 (-0.77%) Jan 22, 7:28 PM
Market Cap 85.89M
Revenue (ttm) n/a
Net Income (ttm) -27.52M
Shares Out 17.25M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $9.07
Previous Close $9.05
Change ($) 0.02
Change (%) 0.22%
Day's Open 8.97
Day's Range 8.50 - 9.47
Day's Volume 19,574
52-Week Range 1.21 - 10.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 day ago

F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value.

GlobeNewsWire - 2 days ago

Patent protects Company's lead clinical asset FS118 throughout Europe Patent protects Company's lead clinical asset FS118 throughout Europe

GlobeNewsWire - 2 weeks ago

FS222 is a potentially best-in-class bispecific antibody targeting CD137 (4-1BB) and PD-L1, and is the Company's third bispecific to enter clinical trials

PRNewsWire - 2 months ago

CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to...

Other stocks mentioned: SBPH
PRNewsWire - 2 months ago

HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release ...

GlobeNewsWire - 2 months ago

1-for-4 Reverse Stock Split to be Effective November 20, 2020 1-for-4 Reverse Stock Split to be Effective November 20, 2020

GlobeNewsWire - 2 months ago

HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics f...

GlobeNewsWire - 2 months ago

HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and ...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SB...

PRNewsWire - 4 months ago

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals,...

PRNewsWire - 4 months ago

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc.

GlobeNewsWire - 5 months ago

Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs

PRNewsWire - 5 months ago

NEW ORLEANS, Aug. 6, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

PRNewsWire - 5 months ago

NEW YORK, Aug. 5, 2020 /PRNewswire/ --Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New ...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spri...

PRNewsWire - 5 months ago

NEW YORK, July 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of director...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the pr...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - July 30, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders...

GlobeNewsWire - 5 months ago

HOPKINTON, Mass. and CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biop...

GlobeNewsWire - 7 months ago

-    Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roc...

GlobeNewsWire - 9 months ago

HOPKINTON, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology a...

Market Watch - 11 months ago

Spring Bank Pharmaceuticals Inc. [s; sbph] said Wednesday it is scrapping the development of inarigivir soproxil, a treatment for chronic hepatitis B virus, after a patient died during a phase...

GlobeNewsWire - 11 months ago

HOPKINTON, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

Zacks Investment Research - 1 year ago

The upbeat sentiments prevailing in Wall Street make investment in small caps stocks attractive for 2020, here's why.

Other stocks mentioned: CHUY, CUBI, DKL, SBPH, UCTT
Zacks Investment Research - 1 year ago

Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.

Market Watch - 1 year ago

Spring Bank Pharmaceutical Inc.'s shares slid 17% in premarket trade Thursday, after the clinical-stage biopharma company said it has stopped dosing patients in a trial of a treatment for chr...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 24th

Other stocks mentioned: DKS, EVA, JOUT, SBPH
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals.

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 11th

Other stocks mentioned: EXPR, GCO, SBPH, SEAC
GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals, Inc. (SBPH).

Seeking Alpha - 1 year ago

Today, we take an in-depth look at Spring Bank Pharmaceuticals.

About FSTX

F-star Therapeutics, a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Industry
Biotechnology
IPO Date
May 6, 2016
CEO
Dr. Eliot Richard Forster M.B.A., Ph.D.
Employees
75
Stock Exchange
NASDAQ
Ticker Symbol
FSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for FSTX stock is "Strong Buy" and the 12-month stock price forecast is 16.50.

Price Target
$16.50
Analyst Consensus: Strong Buy